Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) is set to release its earnings data after the market closes on Wednesday, November 13th. Analysts expect Adaptimmune Therapeutics to post earnings of ($0.17) per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. Adaptimmune Therapeutics had a negative net margin of 51.25% and a negative return on equity of 116.80%. The company had revenue of $128.23 million during the quarter, compared to the consensus estimate of $58.00 million. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Adaptimmune Therapeutics Stock Up 2.6 %
NASDAQ ADAP traded up $0.02 during mid-day trading on Friday, reaching $0.80. The stock had a trading volume of 687,532 shares, compared to its average volume of 1,640,493. The company has a fifty day moving average price of $0.92 and a 200 day moving average price of $1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. Adaptimmune Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.05. The stock has a market cap of $203.80 million, a PE ratio of -2.28 and a beta of 2.26.
Analysts Set New Price Targets
Several equities research analysts recently commented on ADAP shares. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a research report on Tuesday, August 13th. StockNews.com raised shares of Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 13th.
Check Out Our Latest Report on ADAP
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
